AzTrials
AzTrials

Chronic Total Occlusion of Coronary ArteryPETS-CTONCT04145167

Observational Registry on Clinical Outcome After Diagnosis of Chronic Total Occlusions

An observational study of Chronic Total Occlusion of Coronary Artery and Angina Pectoris, run by Ziekenhuis Netwerk Antwerpen (ZNA) at 1 site in Belgium.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This registry aims at enrolling all consecutive patients presenting with at least one chronic total occlusion at coronary angiogram as diagnosed during angiography in our catheterization laboratory during 1 year. Read more about this study

Who is it for?
Ages 18 to 90 years
How many people
400 participants
Where
1 siteBelgium
Study dates
10 Oct 2019to Dec 2022
How long will I take part?
1 Year
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population includes all patients aged >18 with coronary artery disease undergoing coronary catheterization. Key condition to be enrolled in the registry is the evidence of chronic total occlusion and the will to participate in the study.

Who may be able to join

  • Presence of at least one untreated CTO at basal angiography (defined as a total occlusion in any major coronary vessel or relevant side branches [reference vessel diameter ≥2.5mm or as judged by two independent interventional cardiologists], with TIMI 0 in the distal segment and at least 3 months old - according to clinical information or of unknown age).
  • In patients with history of CABG, a CTO can be included when the occlusion is located in a vessel without a graft in the distal vessel or in case of graft occlusion.
  • Age > 18 years
  • Willing to participate and able to understand, read and sign the informed consent document after the diagnostic procedure

Who cannot join

  • Lack of will to participate in the study or inability to provide informed consent (e.g. by patient admitted with cardiac arrest or unconscious)

Trial locations and contacts

1 site in 1 country.

Pierfrancesco Agostoni, MD PhD contact

0032495637041

agostonipf@gmail.com

Belgium1 site, 1 recruiting
  • ZNA Middelheim

    Antwerp, 2020

    Pierfrancesco Agostoni, MD PhD, 0032495637041 ext. 0032495637041, agostonipf@gmail.com

    Pierfrancesco Agostoni, MD PhD

    Recruiting

Other trials in Belgium

About this study

Official title: Prospective Evaluation of Treatment Strategies in Patients Presenting With Chronic Total Occlusions at Coronary Angiogram

This registry aims at enrolling all consecutive patients presenting with at least one chronic total occlusion at coronary angiogram as diagnosed during angiography in our catheterization laboratory during 1 year.

All patients will undergo - whenever possible - a cardiopulmonary excercise test and a non-invasive investigation for myocardial ischemia/viability (by means of echo-dobutamine stress test or perfusion scintigraphy or cardiac magnetic resonance) prior to any eventual revascularization therapy. All patients - including those treated by medical therapy only - will repeat the same investigations after one year of follow-up. In addition to these investigations, clinical outcome and quality of life (including the Seattle Angina Questionnarie and a dedicated depression questionnaire) will be evaluated at baseline and at follow-up.

Primary objective of this study is to investigate the improvement in physical conditions (as expressed by the performance at follow-up CP test), the reduction in ischemia (as evaluated by follow-up non-invasive imaging tests) and the severity of angina according to clinical assessment (including Seattle Angina Questionnaires [SAQ], Canadian Class Score[CCS] and 6-mins walking test).

Read the detailed description

Background The clinical benefits of performing chronic total occlusion (CTO) percutaneous coronary intervention (PCI) represent still a matter of debate in the community of interventional cardiologists[1]. Improvements in terms of symptoms' relief after successful CTO recanalization are growing, with emerging data from randomized clinical trials (RCT) [2] in addition to the already existing large registries[3,4]. In addition, these registries offer data supporting reduction in hard clinical endpoints - including incidence of myocardial infarction (MI) and cardiac death - which however, has so far not been confirmed in RCT. Furthermore, data regarding reduction in ischemia burden after successful CTO-PCI - despite intuitive - and its clinical implications are still lacking, with only a small registry[5] reporting on improved Cardiopulmonary Exercise parameters after successful CTO recanalization. It's also widely known that chronic (refractory) angina significantly impacts the daily life of patients with CTO lesions, not only affecting their quality of life, but also leading to a de-conditioning and a self-limitation in daily activities, creating a negative loop that further reduce the efforts tolerance in these delicate patients. Moreover, recent data suggest that incidence of depression is common among patients with known coronary CTO, and that benefits from successful CTO-PCI may include improvements in psychological health[6].

Of note, the outcome of patients presenting with CTO lesions has been so far investigated only in selected groups of populations (including those with evidence of ischemia/viability, those undergoing CTO-PCI procedures…). However, a systematic and prospective analysis of all consecutive patients presenting with CTO lesions during coronary angiogram, independently by any therapeutic strategy, is so far lacking.

Objective Aim of this registry is to include all consecutive patients presenting with CTO lesion in a relevant coronary vessel (or relevant side branch [namely any coronary vessel with diameter ≥2.5mm]) during cardiac catheterization, to comprehensively analyse their characteristics and to investigate the clinical outcome at 1 year, independently of their therapeutic work-up.

Methodology All patients undergoing coronary angiogram in our centre will be screened for eligibility in the registry. Inclusion and exclusion criteria are here reported.

Inclusion Criteria:

  • Presence of at least one untreated CTO at basal angiography (defined as a total occlusion in any major coronary vessel or relevant side branches [reference vessel diameter ≥2.5mm or as judged by two independent interventional cardiologists], with TIMI 0 in the distal segment and at least 3 months old - according to clinical information or of unknown age).
  • In patients with history of CABG, a CTO can be included when the occlusion is located in a vessel without a graft in the distal vessel or in case of graft occlusion.
  • Age > 18 years
  • Willing to participate and able to understand, read and sign the informed consent document after the diagnostic procedure

By study design, no specific exclusion criteria are indicated, except for the lack of will to participate in the study or inability to provide informed consent (e.g. by patient admitted with cardia arrest or unconscious).

Written informed consent form will be collected in all patients.

Withdrawal criteria Patients will be able to withdraw from the study at any time at their request.

Briefly, all patients fulfilling the inclusion criteria will be enrolled in this registry. Of note, the relevance of the CTO-vessel will be adjudicated by two different experienced interventional cardiologists. CTO of small vessels without haemodynamic relevance will not be included in this study. After evaluation in a dedicated CTO-outpatient clinic, they will undergo a cardiopulmonary exercise test (Baseline CP test) and MIBI-scan before any therapeutic strategy (including CTO-PCI or surgical revascularization).

After one year from the enrolment, patients will be evaluated again in the dedicated outpatient clinic, with repeated imaging and functional tests.

Study Objective Primary objective of this study is the improvement in physical conditions as expressed by the performance at follow-up CP test, the reduction in ischemia as evaluated by follow-up MIBI-scan and the severity of angina according to clinical assessment (including Seattle Angina Questionnaires [SAQ], Canadian Class Score[CCS] and 6-mins walking test). Quality of life will also be assessed by means of a dedicated Depression score. These outcomes will be stratified according to the therapeutic strategy adopted in each patient (namely optimal medical treatment alone, CTO-PCI or surgical revascularization).

Secondary endpoints will include a composite of major adverse clinical events (defined as cardiovascular death, myocardial infarction and ischemia-driven revascularization), re-hospitalization for angina/heart-failure, bleeding episodes, strokes and need for specialist/non-specialist outpatient evaluation because angina in the study period.

Sample Sizing By study design, all consecutive patients presenting with relevant CTO lesions at coronary angiogram will be included in the analysis. Given the explorative nature of this registry (at present no similar studies are available in the literature), a solid sample-sizing cannot be performed.

Considering the reported incidence of CTO lesions - ranging from 15-25% of the coronary angiographies performed - and the procedure-volume of this centre (approximately 4000 coronary angiograms per year), a 1-year of consecutive enrolment should provide a large number of subjects (approximately 600) to investigate with solidity eventual significant improvements in the primary endpoints.

Previous registries have reported on the outcome of CTO-PCI procedures in terms of CPET parameters, enrolling approximately 30 patients [7], however given the purely observational nature of this study and the fact the many patients could result not eligible to perform an exercise test (similarly for the echo-stress investigation), a large patient pool has been selected for the present registry, in order to provide solid data for this analysis and a possibly clear response to this unresolved clinical controversy.

Duration of the study (per patient) The duration of participation for each patient will be approximately 1 year. Patients presenting with evidence of CTO lesions at angiography will be screened and, if meeting the study eligibility criteria, will be enrolled in the study. A comprehensive clinical evaluation, together with cardiopulmonary exercise test and MIBI-scan will be performed in the month following the enrollment. Independently of the subsequent treatment strategies, patients will be followed-up for 1 year, including a new clinical evaluation in outpatient setting with cardiopulmonary test and MIBI-scan at the end of the follow-up.

Keywords
chronic total occlusion, coronary percutaneous intervention, ischemic heart disease
Medical subject headings
Angina Pectoris, Myocardial Ischemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04145167
Study groupRoleWhat they receive
Medical TreatmentThis group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by medical therapy only, for any clinical/angiographic/instrumental indication.
Percutaneous interventionThis group will include all patients with a diagnose of coronary chronic total occlusions who will be treated by percutaneous intervention (CTO-PCI), as indicated by the heart-team.
Surgical treatmentThis group will include all patients with a diagnose of coronary chronic total occlusions (generally not isolated) who will be treated by means of coronary artery by-pass grafting (CABG), as indicated by heart-team decision.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Reduction in ischemia and angina paramteres

    Parameters of Cardiopulmonary Exercise test, non-invasive imaging tests and angina questionnaires.

    Measured: 1 year

Secondary outcomes (3)
  1. Composite of major adverse clinical events

    Composite of cardiac death, myocardial infarction and ischemia-driven revascularization.

    Measured: 1 year

  2. Re-hospitalization

    Episodes of re-hospitalization due to angina/heart-failure

    Measured: 1 year

  3. Outpatient clinic evaluation

    Need for specialist/non-specialist outpatient evaluation because angina

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Oct 2019
  2. Study start10 Oct 2019
  3. Primary completionDec 2021 (estimated)
  4. Study completionDec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
400 participants (estimated)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT04145167
Sponsor's protocol ID
EC 5269
Acronym
PETS-CTO
Status last verified
Jul 2021
First submitted
28 Oct 2019
Last updated
15 Jul 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Tajti P, Brilakis ES. Chronic Total Occlusion Percutaneous Coronary Intervention: Evidence and Controversies. J Am Heart Assoc. 2018 Jan 12;7(2):e006732. doi: 10.1161/JAHA.117.006732. No abstract available.

    PubMed 29330258
  • Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J, di Mario C, Hovasse T, Teruel L, Bufe A, Lauer B, Bogaerts K, Goicolea J, Spratt JC, Gershlick AH, Galassi AR, Louvard Y; EUROCTO trial investigators. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018 Jul 7;39(26):2484-2493. doi: 10.1093/eurheartj/ehy220.

    PubMed 29722796
  • Tomasello SD, Boukhris M, Giubilato S, Marza F, Garbo R, Contegiacomo G, Marzocchi A, Niccoli G, Gagnor A, Varbella F, Desideri A, Rubartelli P, Cioppa A, Baralis G, Galassi AR. Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. Eur Heart J. 2015 Dec 1;36(45):3189-98. doi: 10.1093/eurheartj/ehv450. Epub 2015 Sep 2.

    PubMed 26333367
  • Jang WJ, Yang JH, Choi SH, Song YB, Hahn JY, Choi JH, Kim WS, Lee YT, Gwon HC. Long-term survival benefit of revascularization compared with medical therapy in patients with coronary chronic total occlusion and well-developed collateral circulation. JACC Cardiovasc Interv. 2015 Feb;8(2):271-279. doi: 10.1016/j.jcin.2014.10.010.

    PubMed 25700750
  • Abdullah SM, Hastings JL, Amsavelu S, Garcia-Morales F, Hendrix F, Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle M, Khalili H, Banerjee S, Brilakis ES. Percutaneous Coronary Intervention of Coronary Chronic Total Occlusions Improves Peak Oxygen Uptake During Cardiopulmonary Exercise Testing. J Invasive Cardiol. 2017 Mar;29(3):83-91.

    PubMed 28255103
  • Yeh RW, Tamez H, Secemsky EA, Grantham JA, Sapontis J, Spertus JA, Cohen DJ, Nicholson WJ, Gosch K, Jones PG, Valsdottir LR, Bruckel J, Lombardi WL, Jaffer FA. Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention: The OPEN-CTO Registry. JACC Cardiovasc Interv. 2019 Apr 8;12(7):651-658. doi: 10.1016/j.jcin.2018.12.029. Epub 2019 Mar 13.

    PubMed 30878475
  • Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. No abstract available.

    PubMed 21670242
  • Poletti E, Zivelonghi C, Castaldi G, Vermeersch P, Convens C, Selleslagh P, Prihadi E, Droogmans S, Scott B, Agostoni P. Prospective Evaluation of Treatment Strategies in Patients Presenting With Chronic Total Occlusion: The PETS-CTO Registry. Catheter Cardiovasc Interv. 2025 Jul;106(1):443-453. doi: 10.1002/ccd.31559. Epub 2025 Apr 28.

    PubMed 40296468

Questions about this trial

What is this clinical trial studying?

An observational study of Chronic Total Occlusion of Coronary Artery and Angina Pectoris, run by Ziekenhuis Netwerk Antwerpen (ZNA) at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Pierfrancesco Agostoni, MD PhD (0032495637041, agostonipf@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Reduction in ischemia and angina paramteres (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04145167, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in